NCT02658929 - Study of bb2121 in Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 2015

Primary Completion Date

July 22, 2019

Study Completion Date

September 22, 2022

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

bb2121

Trial Locations (9)

Mt. Sinai Medical Center Division of Hematology/Oncology, New York

National Cancer Institute, Bethesda

Sarah Cannon Research Inst, Nashville

Mayo Clinic, Rochester

Stanford Cancer Center, Stanford

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Hackensack University Medical Center, Hackensack